Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rein Therapeutics, Inc.ALRN · Entity 7071 | Director · See Remarks | July 25, 2017 | July 27, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rein Therapeutics, Inc.
Report date July 25, 2017 · Filed July 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2027-07-24 | Direct | 157,449 |
Reported balance
After 2017-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-25 · Grant · Acquired 157,449 · Balance 157,449 F1: This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from July 25, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from July 25, 2017.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 25, 2017 Filed Jul 27, 2017 22:35 UTC | Rein Therapeutics, Inc. ALRN · Entity 7071 | GrantStock Option (right to buy) · Derivative | 157,449 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019220 · doc4.xml · derivative · entry 1 Yanchik Joseph A., III · CIK 0001618154 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,449 Underlying: Common Stock · 157,449 shares Expires 2027-07-24 F1 · derivative.exercise_date: This option was granted on July 25, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from July 25, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.